PSA screening for prostate cancer reduces disease-specific deaths, new review shows
Why this matters: health reporting relevant to everyday decisions and well-being.
Prostate-specific antigen (PSA) blood testing is likely to reduce the risk of death from prostate cancer, found a new review published on Thursday by an influential international science research organization — a shift in medical evidence that could encourage wider use.&#x A0; The Cochrane review’s first author, Juan Franco from Heinrich Heine University D&#x FC;sseldorf in Germany, said at a press conference that they have “moderate certainty” that the screening test, which identifies high levels of PSA as a potential marker of prostate cancer, leads to a reduction in disease-specific deaths. The benefits are marginal: the review analyzed results from six trials involving 800,000 participants conducted in Europe and North America, and found about two fewer prostate cancer deaths for every 1,000 men screened. Read the rest…